Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

MYC Gene Single Hit Diffuse Large B Cell Lymphoma Behaves Similarly To MYC/BCL2 Double Hit Lymphoma and Needs Similar Aggressive Treatment

Xuan J. Wang, MD, Nishitha M. Reddy, MD, Shaoying Li, MD

Blood (2013) 122 (21): 4313.

https://doi.org/10.1182/blood.V122.21.4313.4313

Published: 2013

Journal Articles

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

Judy Tsai, M.D., John P Greer, MD, David S. Morgan, MD, Shaoying Li, MD, Nishitha M. Reddy, MD

Blood (2013) 122 (21): 4361.

https://doi.org/10.1182/blood.V122.21.4361.4361

Published: 2013

Journal Articles

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Nishitha M. Reddy, MD, David S. Morgan, MD, Steven I. Park, MD, John P Greer, MD, Kristy L. Richards, MD PhD

Blood (2013) 122 (21): 3061.

https://doi.org/10.1182/blood.V122.21.3061.3061

Published: 2013

Journal Articles

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Nishitha M. Reddy, MD, Olalekan O Oluwole, MBBS, MPH, John P Greer, MD, David S Morgan, MD, Stacey Goodman, MD, Brian Engelhardt, MD, Wichai Chinratanalab, MD, Adetola A Kassim, MD, Madan Jagasia, MBBS, MS, Bipin N. Savani, MD

Blood (2012) 120 (21): 2036.

https://doi.org/10.1182/blood.V120.21.2036.2036

Published: 2012

Journal Articles

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Nishitha M. Reddy, MD, Rhea M Simons, RN, Meghan E Caldwell, NP, Heidi Chen, PhD, Madan Jagasia, MBBS, MS, David S Morgan, MD, Steven I. Park, MD, John P Greer, MD, Kristy L. Richards, PhD, MD

Blood (2012) 120 (21): 3668.

https://doi.org/10.1182/blood.V120.21.3668.3668

Published: 2012

Journal Articles

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Patrick L Stevens, MD, Mahsa Talbott, Meghan E Caldwell, NP, David S Morgan, MD, Annette S. Kim, MD, PhD, John P Greer, MD, Nishitha M. Reddy, MD

Blood (2011) 118 (21): 4954.

https://doi.org/10.1182/blood.V118.21.4954.4954

Published: 2011

Journal Articles

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Adam C. Seegmiller, MD, PhD, Annette S. Kim, MD, PhD, Claudio A. Mosse, MD, PhD, Mia A. Levy, MD, PhD, Mary Ann Thompson, MD, PhD, Megan K. Kressin, MD, Madan H. Jagasia, MD, Stephen A. Strickland, MD, MSCI, Nishitha M. Reddy, MD, Kristy J. Sinkfield, Samuel A. Santoro, MD, PhD, Mary M. Zutter, MD

Blood (2011) 118 (21): 2073.

https://doi.org/10.1182/blood.V118.21.2073.2073

Published: 2011

NARROW

MYC Gene Single Hit Diffuse Large B Cell Lymphoma Behaves Similarly To MYC/BCL2 Double Hit Lymphoma and Needs Similar Aggressive Treatment

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Email alerts

ASH Publications

American Society of Hematology

MYC Gene Single Hit Diffuse Large B Cell Lymphoma Behaves Similarly To MYC/BCL2 Double Hit Lymphoma and Needs Similar Aggressive Treatment

Role Of Aggressive Chemotherapeutic Regimens In Double Hit Lymphoma- Can Alternate Aggressive Induction Regimens Overcome The Poor Prognosis Of Diffuse Large B Cell Lymphoma?

Phase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)

Comparison of Autologous Vs. Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma

A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab As Maintenance Therapy Following R-CHOP Chemotherapy for Patients with High Risk Diffuse Large B-Cell Lymphoma

Combination Chemotherapy with Rituximab, Gemcitabine, Vinorelbine and Liposomal Doxorubicin As a Salvage Regimen for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Evidence-Based, Patient-Specific Guidelines Provide Efficient and Cost-Effective Molecular and Cytogenetic Testing in Hematologic Malignancy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only